No Rx for big drugmakers accused of fixing prices

The pharmaceutical industry is in hot water.

For years the Federal Trade Commission has scrutinized drug pricing, taking a hard look at so-called reverse payments that branded drugmakers use to settle...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:

FTCWatch is delivered in the following formats: via email alert and online at